COVID-19 Treatment and Management: Two Years After the Outbreak

authors:

avatar Pouya Safarzadeh Kozani ORCID 1 , avatar Pooria Safarzadeh Kozani ORCID 2 , avatar Narges Baharifar 3 , avatar Mehdi Sheikhi 4 , avatar Fatemeh Kiani 3 , avatar Forough Chamaie Nejad 3 , avatar Seyed Mohamad Javad Mirarefin 5 , avatar Abdolkarim Sheikhi ORCID 3 , *

Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
Faculty of Medicine, Islamic Azad University, Kazeroon Branch, Kazeroon, Iran
Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

how to cite: Safarzadeh Kozani P , Safarzadeh Kozani P, Baharifar N, Sheikhi M, Kiani F, et al. COVID-19 Treatment and Management: Two Years After the Outbreak. J Adv Immunopharmacol. 2022;2(2):e127016. https://doi.org/10.5812/tms-127016.

References

  • 1.

    BMJ. Update to living WHO guideline on drugs for covid-19. BMJ. 2020;371:m4475. [PubMed ID: 33214213]. https://doi.org/10.1136/bmj.m4475.

  • 2.

    Burki TK. The role of antiviral treatment in the COVID-19 pandemic. Lancet Respir Med. 2022;10(2). https://doi.org/10.1016/s2213-2600(22)00011-x.

  • 3.

    Lamb YN. Nirmatrelvir Plus Ritonavir: First Approval. Drugs. 2022:1-7.

  • 4.

    Moreno S, Alcazar B, Duenas C, Gonzalez Del Castillo J, Olalla J, Antela A. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir. Drug Des Devel Ther. 2022;16:827-41. [PubMed ID: 35370401]. [PubMed Central ID: PMC8965332]. https://doi.org/10.2147/DDDT.S356951.

  • 5.

    Gupta I, Arguello Perez ES. Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection. Cureus. 2022;14(2). https://doi.org/10.7759/cureus.22658.

  • 6.

    Bavaro DF, Diella L, Solimando AG, Cicco S, Buonamico E, Stasi C, et al. Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection. Pathog Glob Health. 2022:1-8. [PubMed ID: 35138229]. [PubMed Central ID: PMC8862158]. https://doi.org/10.1080/20477724.2021.2024030.

  • 7.

    Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, de Luca G, et al. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert Opin Drug Discov. 2022:1-16. [PubMed ID: 35361043]. https://doi.org/10.1080/17460441.2022.2058486.

  • 8.

    The Medical Letter on Drugs and Therapeutics. COVID-19 Updates: Increased dosage of tixagevimab/cilgavimab (Evusheld). Med Lett Drugs Ther. 2022;64(1646):48. [PubMed ID: 35294430].

  • 9.

    Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020;323(15):1499-500. [PubMed ID: 32159735]. https://doi.org/10.1001/jama.2020.3633.

  • 10.

    Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care. 2020;58:27-8. [PubMed ID: 32279018]. [PubMed Central ID: PMC7118619]. https://doi.org/10.1016/j.jcrc.2020.03.011.